Literature DB >> 30334449

Long non-coding RNA CRNDE may be associated with poor prognosis by promoting proliferation and inhibiting apoptosis of cervical cancer cells through targeting PI3K/AKT.

H Y Yang1, C P Huang1, M M Cao1, Y F Wang1, Y Liu1.   

Abstract

Long non-coding RNAs (lncRNAs) are attracting more and more attention from researchers because they are relatively new factors in regulating biological processes in human cancers. The Colorectal Neoplasia Differentially Expressed (CRNDE) lncRNA is transcribed from chromosome 16 on the opposite strand to the neighboring IRX5 gene. It was originally discovered abnormally expressed in colorectal cancer (CRC) and was certified a critical biomarker in many cancers. However, its biological function and mechanism underlying the tumorigenesis of cervical cancer still require exploration. This study confirmed that CRNDE is markedly up-regulated in clinical tissues and cell lines of cervical cancer. The high expression of CRNDE positively correlates with advanced FIGO stage and lymph node metastasis. Furthermore, the overall survival rate in the group with highly expressed CRNDE was worse, and the high level of CRNDE may be regarded a prognostic factor because of its results from proportional hazard analysis. Loss-of-function assays revealed that CRNDE influences proliferation and apoptosis in cervical cancer cells, and Western blot assays revealed that the PI3K/AKT pathway was inactivated in response to CRNDE knockdown. Therefore, we conclude that CRNDE exerts oncogenic function in cervical cancer and should be further explored as a novel prognostic predictor.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30334449     DOI: 10.4149/neo_2018_171225N841

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  9 in total

1.  Long non-coding RNA CRNDE promote the progression of tongue squamous cell carcinoma through regulating the PI3K/AKT/mTOR signaling pathway.

Authors:  Zhongheng Yang; Weizhi Chen
Journal:  RSC Adv       Date:  2019-07-10       Impact factor: 4.036

Review 2.  CRNDE: an oncogenic long non-coding RNA in cancers.

Authors:  Ya Lu; Huanhuan Sha; Xun Sun; Yuan Zhang; Yang Wu; Junying Zhang; Hui Zhang; Jianzhong Wu; Jifeng Feng
Journal:  Cancer Cell Int       Date:  2020-05-12       Impact factor: 5.722

Review 3.  Targeting PI3K in cancer: mechanisms and advances in clinical trials.

Authors:  Jing Yang; Ji Nie; Xuelei Ma; Yuquan Wei; Yong Peng; Xiawei Wei
Journal:  Mol Cancer       Date:  2019-02-19       Impact factor: 27.401

Review 4.  Roles and Mechanisms of the Long Noncoding RNAs in Cervical Cancer.

Authors:  Miguel Ángel Cáceres-Durán; Ândrea Ribeiro-Dos-Santos; Amanda Ferreira Vidal
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

Review 5.  CRNDE: A valuable long noncoding RNA for diagnosis and therapy of solid and hematological malignancies.

Authors:  Xuefei Ma; Wen Jin; Chaoxian Zhao; Xuefeng Wang; Kankan Wang
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-09       Impact factor: 8.886

Review 6.  Emerging Roles and Potential Applications of Non-Coding RNAs in Cervical Cancer.

Authors:  Deepak Parashar; Anupam Singh; Saurabh Gupta; Aishwarya Sharma; Manish K Sharma; Kuldeep K Roy; Subhash C Chauhan; Vivek K Kashyap
Journal:  Genes (Basel)       Date:  2022-07-15       Impact factor: 4.141

Review 7.  Long noncoding RNAs (lncRNAs) in HIV-mediated carcinogenesis: Role in cell homeostasis, cell survival processes and drug resistance.

Authors:  Lilian Makgoo; Salerwe Mosebi; Zukile Mbita
Journal:  Noncoding RNA Res       Date:  2022-07-31

8.  CRNDE silencing promotes apoptosis and enhances cisplatin sensitivity of colorectal carcinoma cells by inhibiting the Akt/mTORC1-mediated Warburg effect.

Authors:  Wenyu Yang; Yanchun Wang; Chunhui Tao; Yunhai Li; Shan Cao; Xiqian Yang
Journal:  Oncol Lett       Date:  2022-01-05       Impact factor: 2.967

Review 9.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.